Growth Hormone-secreting adenomas exhibits variable biological behavior and
heterogeneous natural history, ranging from small adenomas and mild disease, to invasive …

Aggressive GH-secreting pituitary adenomas (GHPAs) represent an important clinical
problem in patients with acromegaly. Surgical therapy, although often the mainstay of …

Background Transsphenoidal adenomectomy (TSS) of somatotroph pituitary
neuroendocrine tumor (PitNET) is the first-line treatment of acromegaly. Pharmacological …

This review aimed to highlight the history, diagnostic criteria, preoperative prognostic factors,
surgical management, and multimodal adjuvant therapies recommended to provide a …

Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous
evidence supporting available treatment approaches. Recent guidelines emphasize the …

Context: GH-secreting pituitary adenomas exhibit heterogeneous natural history ranging
from small tumors to large aggressive adenomas. Objective: To rigorously classify an …

Refractory pituitary adenomas (PAs) are defined as aggressive-invasive PAs characterized
by rapid growth, frequent recurrence, a high Ki-67 index, and resistance to standard …

OBJECTIVE Acromegaly results in disfiguring growth and numerous medical complications.
This disease is typically caused by growth hormone (GH)–secreting pituitary adenomas …

With a prevalence of 80–100/100000, pituitary adenomas are more frequent than thought.
The rare aggressive pituitary adenoma presents a special challenge, due to the …

The majority of acromegaly and gigantism are caused by growth hormone‐secreting
pituitary neuroendocrine tumors (PitNETs). Most cases can be cured or controlled by …